X
<

What Drove Eli Lilly in 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 9
What Drove Eli Lilly in 3Q17? PART 9 OF 12

An Update on Eli Lilly’s Oncology Drugs: Alimta, Erbitux, and Gemzar

Alimta revenue trends

In 3Q17, Eli Lilly’s (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis. In 3Q17, in the US and international markets (outside US markets), Alimta generated revenues of $260.3 million and $254.2 million, respectively, compared to $277.0 million and $293.4 million in 3Q16.

Alimta reported revenues of $1.5 billion in the first nine months of 2017. In the US and international markets, Alimta generated revenues of $761.9 million and $775.4 million in the first nine months of 2017, respectively. Alimta is Eli Lilly’s blockbuster drug for the treatment of advanced nonsquamous non-small cell lung cancer (or NSCLC).

An Update on Eli Lilly’s Oncology Drugs: Alimta, Erbitux, and Gemzar

Interested in VHT? Don't miss the next report.

Receive e-mail alerts for new research on VHT

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Erbitux revenue trends

In 3Q17, Erbitux generated revenues of $163.5 million, a ~11% decline on a YoY basis and 3% growth on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Erbitux generated revenues of $136.0 million and $27.4 million, respectively, compared to $154.4 million and $30.2 million in 3Q16.

Erbitux reported YTD September 2017 revenues of $477 million. In the US and international markets, Erbitux reported YTD September 2017 revenues of $398.2 million and $78.8 million, respectively. In the colorectal cancer market, Erbitux competes with Roche’s (RHHBY) Avastin, Bristol-Myers Squibb’s (BMY) Opdivo, and Amgen’s (AMGN) Vectibix. In 3Q17, Vectibix reported revenues of $168 million.

Gemzar and Lartruvo revenue trends

In 3Q17, Gemzar reported revenues of $26.9 million, a ~4% decline on a YoY basis and a 3% decline on a quarter-over-quarter basis. Gemzar reported revenues of $80.5 million in the first nine months of 2017.

In 3Q17, Lartruvo reported revenues of $54.5 million, which reflected ~15% growth on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Lartruvo reported revenues of $42.4 million and $12.0 million, respectively.

The Vanguard Health Care ETF (VHT) invests ~2.0% of its total portfolio holding in Eli Lilly.

X

Please select a profession that best describes you: